An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
about
The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinasesBcr-Abl oncoproteins bind directly to activators of the Ras signalling pathwayActivation of murine c-abl protooncogene: effect of a point mutation on oncogenic activationTranscriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinasesActivation of the receptor kinase domain of the trk oncogene by recombination with two different cellular sequencesThe t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcriptGeneration of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemiaThe (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemiaThe translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNAInterferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cellsThe first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemiaThe chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcriptret transforming gene encodes a fusion protein homologous to tyrosine kinasesCan, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set geneThe amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulationChronic myeloid leukemia: reminiscences and dreamsSystems genetics for drug target discoveryMolecular pathology of cancer: how to communicate with diseaseAbl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinaseThe LIM protein FHL3 binds basic Krüppel-like factor/Krüppel-like factor 3 and its co-repressor C-terminal-binding protein 2The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domainsBCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with CrklRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorInhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexesMolecular cloning and characterization of TPP36 and its isoform TPP32, novel substrates of Abl tyrosine kinaseMutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitorMolecular mechanisms of cancer.Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Two forms of the basic fibroblast growth factor receptor-like mRNA are expressed in the developing mouse brainBCR/ABL transcripts and leukemia phenotype: an unsolved puzzle.Biology-driven cancer drug development: back to the futureClinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.Identification and subcellular localization of proteins that are rapidly phosphorylated in tyrosine in response to colony-stimulating factor 1STAT signaling in the pathogenesis and treatment of cancerInduction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemiabcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
P2860
Q24292892-E16CB366-B7E5-4774-AAEE-D3356567E604Q24324144-5285BCD7-8824-494F-91E2-D7D57B41C815Q24557464-76CD9F63-DEC0-4481-9FF3-9F4D7A375779Q24564193-18764890-6AB2-464B-B772-040D821CE1E6Q24564358-102C0812-08C8-4B6B-A19D-BE141E45876DQ24564573-39B14F2E-B70D-4AA0-8EAF-03344926513AQ24596770-DBBFB3BF-4CE9-411D-88A5-30C11ED54AA1Q24598594-F0135077-CC3A-4540-ABAA-7434BF463A08Q24599829-2C1A44F4-AC37-43DC-9DFE-F9F4ACA40C42Q24606378-643FD4D5-E535-47AC-87D1-84CA2467BEB9Q24611533-A8260C2C-0402-45F4-A7DE-A1A0BCA30765Q24613429-85EED097-0688-4963-ABE3-2395B6B00689Q24615435-1BAE98FF-34D8-4E1B-987F-DE513374570CQ24628687-9A9D5D14-FCD3-4B49-A5EA-6B01B36146AAQ24629998-2EA4DF69-78B3-4D6E-8487-8D16104E86B1Q24649024-AABB6C58-9197-4EBD-953F-0D64DDB5E47CQ26748769-376A6540-A118-4C7C-AEBB-0E61A77B57ECQ27012769-54B8E009-A401-40E4-A5CC-608909ACF579Q28076360-2D486BC8-57D6-4D81-9F2F-1AC9538D7F70Q28188375-7EA83817-AD12-483E-B4E4-5EE6F4E335AFQ28205922-72D6D97F-0F17-424F-A9A6-4899BA9BB953Q28210453-81334D38-61A9-4CD7-B230-64141DCCE273Q28257171-C9C44961-6C23-4FBE-93C5-99FDE4A84B5BQ28482297-19A20F87-099D-4905-9DBC-D11705BBB314Q28506023-638F4736-AFEF-4B0B-BAAC-97D9C28B802FQ28511791-D5605262-F52D-4C8C-834B-D516A6B5792EQ30192925-E844F78F-1B0C-4B05-99D7-AA73DB166A75Q30195654-6476300D-B372-4E75-8F0A-C170A7C4C727Q30498610-ABA36CA5-B8A6-4B2D-84F9-8FBD9743313CQ30664269-633C89CA-5640-4887-BFFF-F9CDE2D93BD7Q33253201-A3B510BF-A8F9-4795-BD04-85463F143A0DQ33368284-B076F440-E7DD-418D-8240-3415CFBF63C8Q33552888-55EFC62A-2468-48C9-9D24-666395E47B34Q33602552-EA2C0CBC-E8C4-4211-A0E5-9308A83B85B0Q33636924-ED26B446-81B4-4B38-8106-3E8B12593559Q33662227-F287797D-5504-4C93-9255-AAEF5DA8E32EQ33712802-F0752C46-1986-40DC-928F-91BF4B94DB12Q33764518-B2820E53-897A-471C-BC12-542A32D800B6Q33867942-A7317376-784A-40BA-8A3D-73EA93CA0007Q33919315-42640801-9689-4BDC-A473-5FBAB2A5CD27
P2860
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
description
1984 nî lūn-bûn
@nan
1984 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
An alteration of the human c-a ...... ated tyrosine kinase activity.
@ast
An alteration of the human c-a ...... ated tyrosine kinase activity.
@en
An alteration of the human c-a ...... ated tyrosine kinase activity.
@nl
type
label
An alteration of the human c-a ...... ated tyrosine kinase activity.
@ast
An alteration of the human c-a ...... ated tyrosine kinase activity.
@en
An alteration of the human c-a ...... ated tyrosine kinase activity.
@nl
prefLabel
An alteration of the human c-a ...... ated tyrosine kinase activity.
@ast
An alteration of the human c-a ...... ated tyrosine kinase activity.
@en
An alteration of the human c-a ...... ated tyrosine kinase activity.
@nl
P1433
P1476
An alteration of the human c-a ...... iated tyrosine kinase activity
@en
P2093
S M Watanabe
P304
P356
10.1016/0092-8674(84)90438-0
P407
P577
1984-07-01T00:00:00Z